Advertisement

Gov. Abbott, DSHS sending cases of remdesivir to Midland and Odessa

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)
In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)(WHSV)
Published: Jul. 4, 2020 at 5:20 PM CDT
Email this link
Share on Pinterest
Share on LinkedIn

ODESSA, Texas (KOSA) - Governor Greg Abbott is sending cases of remdesivir to hospitals in Midland and Odessa.

The following comes from Governor Greg Abbott’s office:

Governor Greg Abbott today announced that the Texas Department of State Health Services (DSHS) is distributing five cases of the antiviral drug remdesivir to three hospitals across the Midland-Odessa metropolitan area.

These cases have been provided to DSHS through the U.S. Department of Health and Human Services. This is the sixth round of distribution from the federal government. At 448 cases, this is the largest distribution and is enough to treat approximately 1,792 patients.

This brings the state total to 1,425 cases distributed since May 12.

”As Texas faces an increase in COVID-19 cases and hospitalizations, we remain committed to providing healthcare professionals with the resources they need to respond to this surge and support COVID-19 patients,” said Governor Abbott. “The State of Texas is grateful to the U.S. Department of Health and Human Services for their continued assistance to equip Texas hospitals with Remdesivir. As we continue to combat the virus, Texas remains committed to keeping our communities healthy and safe.”Remdesivir has shown promise in early trials in speeding up the recovery time among hospitalized COVID-19 patients. Using a five-day average of hospitalization data, DSHS used county weighting of the number of COVID positive patients in hospitals to determine the number of remdesivir cases per county. Children’s hospitals are eligible this round due to the powder formulation of the medication.Medical staff at each hospital will determine how the drug will be used, though it must be prescribed in accordance with the Food and Drug Administration’s Emergency Use Authorization, allowing for the treatment of suspected or confirmed COVID-19 in adults and children hospitalized with severe disease, such as those in intensive care. Preliminary results from a clinical trial showed the average recovery time among patients who received remdesivir was 11 days versus 15 days with a placebo. The supply is part of a donation from drug maker Gilead.

Copyright 2020 KOSA. All rights reserved.

Latest News

Latest News